Protocol for a Randomized Phase II/III Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Extended-Release Metformin in Amnestic Mild Cognitive Impairment
Observational studies and pilot trials suggest that metformin may help prevent cognitive decline in neurodegenerative disorders. This clinical trial aims to assess metformin's potential in preventing cognitive decline in at-risk individuals and its impact on biomarkers indicative of disease modification.
Authors
- Kenichi Oishi (ORCID: https://orcid.org/0000-0002-1200-8611)
- Gayane Yenokyan (ORCID: https://orcid.org/0000-0003-1482-5612)
- José A. Luchsinger (ORCID: https://orcid.org/0000-0002-5886-3648)
- Davangere P. Devanand (ORCID: https://orcid.org/0000-0001-8597-1380)
- Joshua Betz (ORCID: https://orcid.org/0000-0003-4488-9799)
- Daniel F. Hanley (ORCID: https://orcid.org/0000-0002-9536-4258)
- Stephanie A. Mayers (ORCID: https://orcid.org/0000-0002-7519-8547)
- Suzanne L. Baker (ORCID: https://orcid.org/0000-0003-0209-3127)
- Terry E. Goldberg (ORCID: https://orcid.org/0000-0002-2455-7247)
- Sam Cammack
- Susan Landau (ORCID: https://orcid.org/0000-0003-4826-6134)
- William Jagust
- Lindsay M. Eyzaguirre
- Gabriela Hernández-Santiago
Institutions
- Johns Hopkins University (US)
- Vanderbilt University (US)
- Columbia University Irving Medical Center (US)
- University of California, Berkeley (US)
Publication Details
- Journal
- Alzheimer Disease & Associated Disorders
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1097/wad.0000000000000677
- Citations
- 5
- Primary Topic
- Diet and metabolism studies
- Type
- article
- Field-Weighted Citation Impact
- 5.82